Regeneron Pharmaceuticals just scooped up 23andMe and its treasure trove of 15 million customer DNA profiles for a bargain basement $256 million – which works out to roughly $2.56 per genetic ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron to buy bankrupt DNA testing firm ...

Through the deal, Regeneron aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of over 15 million customer DNA profiles, collected via its popular ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth of ...

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on the deal's impact looms.

Regeneron said Monday it will "prioritize the privacy, security and ethical use" of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt 23andMe ...

The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including al ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Posted 2025-05-19T12:22:14+00:00 - Updated 2025 ...